Amgen Earnings Estimate

AMGN Stock  USD 313.71  1.07  0.34%   
The next projected EPS of Amgen is estimated to be 4.2736 with future projections ranging from a low of 3.89 to a high of 5.11. Amgen's most recent 12-month trailing earnings per share (EPS TTM) is at 7.56. Please be aware that the consensus of earnings estimates for Amgen Inc is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Amgen is projected to generate 4.2736 in earnings per share on the 31st of March 2025. Amgen earnings estimates show analyst consensus about projected Amgen Inc EPS (Earning Per Share). It derives the highest and the lowest estimates based on Amgen's historical volatility. Many public companies, such as Amgen, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm.

Amgen Revenue Breakdown by Earning Segment

By analyzing Amgen's earnings estimates, investors can diagnose different trends across Amgen's analyst sentiment over time as well as compare current estimates against different timeframes. As of the 17th of March 2025, Gross Profit is likely to grow to about 21.6 B. Also, Pretax Profit Margin is likely to grow to 0.24
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

Amgen Earnings Estimation Breakdown

The calculation of Amgen's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Amgen is estimated to be 4.2736 with the future projection ranging from a low of 3.89 to a high of 5.11. Please be aware that this consensus of annual earnings estimates for Amgen Inc is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
5.31
3.89
Lowest
Expected EPS
4.2736
5.11
Highest

Amgen Earnings Projection Consensus

Suppose the current estimates of Amgen's value are higher than the current market price of the Amgen stock. In this case, investors may conclude that Amgen is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Amgen's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of March 2025Current EPS (TTM)
3195.59%
5.31
4.2736
7.56

Amgen Earnings History

Earnings estimate consensus by Amgen Inc analysts from Wall Street is used by the market to judge Amgen's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Amgen's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.

Amgen Quarterly Gross Profit

5.97 Billion

As of the 17th of March 2025, Earnings Yield is likely to grow to 0.03, though Retained Earnings are likely to grow to (26.2 B). As of the 17th of March 2025, Common Stock Shares Outstanding is likely to grow to about 751.1 M, while Net Income Applicable To Common Shares is likely to drop about 5 B.
Hype
Prediction
LowEstimatedHigh
313.16314.68316.20
Details
Intrinsic
Valuation
LowRealHigh
282.34338.49340.01
Details
Naive
Forecast
LowNextHigh
311.14312.66314.17
Details
32 Analysts
Consensus
LowTargetHigh
290.61319.35354.48
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Amgen. Your research has to be compared to or analyzed against Amgen's peers to derive any actionable benefits. When done correctly, Amgen's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Amgen Inc. Note that many institutional investors and large investment bankers can move markets due to the volume of Amgen assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Amgen. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Amgen's stock price in the short term.

Amgen Earnings per Share Projection vs Actual

Actual Earning per Share of Amgen refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Amgen Inc predict the company's earnings will be in the future. The higher the earnings per share of Amgen, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Amgen Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Amgen, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Amgen should always be considered in relation to other companies to make a more educated investment decision.

Amgen Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Amgen's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2025-02-04
2024-12-315.0755.310.235
2024-10-30
2024-09-305.115.580.47
2024-08-06
2024-06-305.014.97-0.04
2024-05-02
2024-03-313.873.960.09
2024-02-06
2023-12-314.614.710.1
2023-10-31
2023-09-304.674.960.29
2023-08-03
2023-06-304.495.00.5111 
2023-04-27
2023-03-313.853.980.13
2023-01-31
2022-12-314.14.09-0.01
2022-11-03
2022-09-304.444.70.26
2022-08-04
2022-06-304.44.650.25
2022-04-27
2022-03-314.094.250.16
2022-02-07
2021-12-314.084.360.28
2021-11-02
2021-09-304.274.670.4
2021-08-03
2021-06-304.094.380.29
2021-04-27
2021-03-314.053.7-0.35
2021-02-02
2020-12-313.393.810.4212 
2020-10-28
2020-09-303.814.370.5614 
2020-07-28
2020-06-303.824.250.4311 
2020-04-30
2020-03-313.764.170.4110 
2020-01-30
2019-12-313.473.640.17
2019-10-29
2019-09-303.533.660.13
2019-07-30
2019-06-303.593.970.3810 
2019-04-30
2019-03-313.483.560.08
2019-01-29
2018-12-313.273.420.15
2018-10-30
2018-09-303.453.690.24
2018-07-26
2018-06-303.543.830.29
2018-04-24
2018-03-313.233.470.24
2018-02-01
2017-12-313.032.89-0.14
2017-10-25
2017-09-303.113.270.16
2017-07-25
2017-06-303.113.270.16
2017-04-26
2017-03-3133.150.15
2017-02-02
2016-12-312.792.890.1
2016-10-27
2016-09-302.793.020.23
2016-07-27
2016-06-302.742.840.1
2016-04-28
2016-03-312.62.90.311 
2016-01-28
2015-12-312.292.610.3213 
2015-10-28
2015-09-302.382.720.3414 
2015-07-30
2015-06-302.432.570.14
2015-04-21
2015-03-312.12.480.3818 
2015-01-27
2014-12-312.052.160.11
2014-10-27
2014-09-302.112.30.19
2014-07-29
2014-06-302.072.370.314 
2014-04-22
2014-03-311.941.87-0.07
2014-01-28
2013-12-311.681.820.14
2013-10-22
2013-09-301.771.940.17
2013-07-30
2013-06-301.741.890.15
2013-04-23
2013-03-311.841.960.12
2013-01-23
2012-12-311.381.40.02
2012-10-23
2012-09-301.471.670.213 
2012-07-26
2012-06-301.541.830.2918 
2012-04-24
2012-03-311.451.610.1611 
2012-01-26
2011-12-311.221.21-0.01
2011-10-24
2011-09-301.291.40.11
2011-07-29
2011-06-301.281.370.09
2011-04-20
2011-03-311.291.340.05
2011-01-24
2010-12-311.111.170.06
2010-10-25
2010-09-301.271.360.09
2010-07-29
2010-06-301.31.380.08
2010-04-21
2010-03-311.231.30.07
2010-01-25
2009-12-311.121.05-0.07
2009-10-21
2009-09-301.271.490.2217 
2009-07-27
2009-06-301.161.290.1311 
2009-04-23
2009-03-311.151.08-0.07
2009-01-26
2008-12-311.071.06-0.01
2008-10-22
2008-09-301.081.230.1513 
2008-07-28
2008-06-301.021.140.1211 
2008-04-24
2008-03-311.041.120.08
2008-01-24
2007-12-310.971.00.03
2007-10-24
2007-09-301.031.080.05
2007-07-26
2007-06-301.061.120.06
2007-04-23
2007-03-311.081.080.0
2007-01-25
2006-12-310.950.9-0.05
2006-10-23
2006-09-300.981.040.06
2006-07-20
2006-06-300.941.050.1111 
2006-04-18
2006-03-310.890.910.02
2006-01-26
2005-12-310.760.75-0.01
2005-10-19
2005-09-300.820.850.03
2005-07-19
2005-06-300.720.880.1622 
2005-04-21
2005-03-310.670.720.05
2005-01-27
2004-12-310.610.58-0.03
2004-10-20
2004-09-300.620.640.02
2004-07-22
2004-06-300.60.620.02
2004-04-22
2004-03-310.550.570.02
2004-01-22
2003-12-310.480.46-0.02
2003-10-21
2003-09-300.510.530.02
2003-07-22
2003-06-300.460.490.03
2003-04-22
2003-03-310.390.420.03
2003-01-23
2002-12-310.350.350.0
2002-10-23
2002-09-300.320.340.02
2002-07-24
2002-06-300.350.380.03
2002-04-25
2002-03-310.320.320.0
2002-01-23
2001-12-310.310.3-0.01
2001-10-25
2001-09-300.290.30.01
2001-07-26
2001-06-300.280.30.02
2001-04-26
2001-03-310.270.280.01
2001-01-24
2000-12-310.250.24-0.01
2000-10-26
2000-09-300.270.290.02
2000-07-26
2000-06-300.270.280.01
2000-04-25
2000-03-310.250.250.0
2000-01-25
1999-12-310.250.260.01
1999-10-20
1999-09-300.240.280.0416 
1999-07-12
1999-06-300.230.250.02
1999-04-20
1999-03-310.220.230.01
1999-01-28
1998-12-310.210.230.02
1998-10-27
1998-09-300.20.210.01
1998-07-22
1998-06-300.180.210.0316 
1998-04-22
1998-03-310.170.180.01
1998-01-22
1997-12-310.170.170.0
1997-10-22
1997-09-300.170.170.0
1997-07-15
1997-06-300.180.180.0
1997-04-17
1997-03-310.160.160.0
1997-01-23
1996-12-310.160.160.0
1996-10-15
1996-09-300.150.160.01
1996-07-18
1996-06-300.150.160.01
1996-04-17
1996-03-310.130.130.0

About Amgen Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Amgen earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Amgen estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Amgen fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-27.6 B-26.2 B
Retained Earnings Total Equity-25.8 B-24.5 B
Earnings Yield 0.03  0.03 
Price Earnings Ratio 34.48  32.75 
Price Earnings To Growth Ratio(0.87)(0.82)

Pair Trading with Amgen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amgen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amgen will appreciate offsetting losses from the drop in the long position's value.

Moving together with Amgen Stock

  0.87VALN Valneva SE ADR Earnings Call TomorrowPairCorr

Moving against Amgen Stock

  0.82ME 23Andme HoldingPairCorr
  0.79VINC Vincerx PharmaPairCorr
  0.77VKTX Viking TherapeuticsPairCorr
  0.75VANI Vivani Medical Earnings Call This WeekPairCorr
  0.73VERA Vera TherapeuticsPairCorr
The ability to find closely correlated positions to Amgen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amgen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amgen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amgen Inc to buy it.
The correlation of Amgen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amgen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amgen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amgen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Amgen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amgen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amgen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Amgen Inc Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.19)
Dividend Share
9
Earnings Share
7.56
Revenue Per Share
62.242
Quarterly Revenue Growth
0.109
The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.